Bicocca Open Archive

Logo unimib boa
LAPADULA, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.755
AS - Asia 9.538
EU - Europa 6.244
SA - Sud America 1.509
Continente sconosciuto - Info sul continente non disponibili 772
AF - Africa 240
OC - Oceania 10
Totale 31.068
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.922
SG - Singapore 3.501
IT - Italia 1.882
VN - Vietnam 1.720
HK - Hong Kong 1.415
CN - Cina 1.390
BR - Brasile 1.104
RU - Federazione Russa 1.016
SE - Svezia 658
CA - Canada 646
DE - Germania 609
IE - Irlanda 575
FR - Francia 319
BD - Bangladesh 301
GB - Regno Unito 275
IN - India 253
UA - Ucraina 183
FI - Finlandia 162
ID - Indonesia 154
AR - Argentina 138
AT - Austria 137
MX - Messico 108
NL - Olanda 108
TR - Turchia 106
KR - Corea 105
IQ - Iraq 94
ZA - Sudafrica 77
JP - Giappone 69
EC - Ecuador 68
PK - Pakistan 67
PH - Filippine 61
CO - Colombia 54
ES - Italia 54
SA - Arabia Saudita 54
PL - Polonia 51
RO - Romania 49
VE - Venezuela 43
UZ - Uzbekistan 39
MA - Marocco 36
DK - Danimarca 30
CL - Cile 27
PY - Paraguay 26
KE - Kenya 23
CZ - Repubblica Ceca 22
MY - Malesia 21
BE - Belgio 20
JO - Giordania 20
TN - Tunisia 20
ET - Etiopia 19
UY - Uruguay 18
AL - Albania 17
LT - Lituania 17
PE - Perù 17
KZ - Kazakistan 16
AE - Emirati Arabi Uniti 15
IR - Iran 15
JM - Giamaica 15
NP - Nepal 15
CR - Costa Rica 13
DZ - Algeria 13
CH - Svizzera 12
EG - Egitto 12
OM - Oman 12
TH - Thailandia 12
HN - Honduras 10
PA - Panama 10
BO - Bolivia 9
IL - Israele 9
LB - Libano 9
AU - Australia 8
BH - Bahrain 8
PS - Palestinian Territory 8
TT - Trinidad e Tobago 8
AZ - Azerbaigian 7
GE - Georgia 7
MD - Moldavia 7
GR - Grecia 6
PT - Portogallo 6
SN - Senegal 6
TW - Taiwan 6
GT - Guatemala 5
LY - Libia 5
NG - Nigeria 5
SY - Repubblica araba siriana 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
EE - Estonia 4
KG - Kirghizistan 4
LV - Lettonia 4
NI - Nicaragua 4
PR - Porto Rico 4
UG - Uganda 4
AM - Armenia 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
GY - Guiana 3
HU - Ungheria 3
AO - Angola 2
BT - Bhutan 2
BW - Botswana 2
Totale 30.247
Salva come PNG Salva come JPEG
Città #
Singapore 2.004
Hong Kong 1.386
Ashburn 1.025
Ann Arbor 987
San Jose 974
Fairfield 590
Dublin 558
Milan 516
Woodbridge 491
Ho Chi Minh City 489
Toronto 487
Chandler 466
Dallas 458
Houston 439
Hanoi 424
New York 393
Frankfurt am Main 375
Santa Clara 316
Los Angeles 314
Chicago 305
Wilmington 293
Princeton 230
Seattle 228
Hefei 227
Beijing 199
Cambridge 196
Jacksonville 196
The Dalles 190
Rome 176
Lauterbourg 136
Dearborn 130
Moscow 121
Buffalo 119
Jakarta 113
Altamura 111
Lawrence 111
Council Bluffs 103
Paris 92
Seoul 92
Vienna 88
São Paulo 81
Helsinki 79
Shanghai 78
San Diego 67
Da Nang 63
Haiphong 61
Tokyo 61
Boardman 59
Nuremberg 56
London 54
Nanjing 53
Munich 50
Montreal 47
Dong Ket 44
Warsaw 44
Galati 43
Orem 42
Atlanta 41
Johannesburg 41
Baghdad 39
Biên Hòa 37
Brooklyn 37
Lachine 37
Tashkent 37
Hải Dương 35
Lappeenranta 32
Rio de Janeiro 31
Amsterdam 30
Andover 30
Denver 30
Guangzhou 30
Naples 30
Palermo 30
Chennai 29
Phoenix 29
Salt Lake City 29
Bologna 27
Kent 27
Pune 26
Quận Bình Thạnh 26
Brasília 25
Mexico City 25
Poplar 25
Quito 25
Stockholm 25
Turin 25
Ha Long 24
Belo Horizonte 23
Columbus 23
Figino 23
Thái Nguyên 23
Washington 23
Curitiba 22
Jeddah 22
Vũng Tàu 22
Boston 21
Bogotá 19
Brussels 19
Addis Ababa 18
Can Tho 18
Totale 18.320
Salva come PNG Salva come JPEG
Nome #
Behavioural survey and street-based HIV and HCV rapid testing programme among transgender sex workers 568
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 413
Unexpected HBV reactivation following discontinuation of antiviral prophylaxis in immunosuppressed subjects with previous HBV exposure 407
Remdesivir use in patients requiring mechanical ventilation due to COVID-19 399
Caratteristiche di una coorte di pazienti con co-infezione HIV/HCV: i dati dell’Ambulatorio di Malattie Infettive dell’Ospedale San Gerardo di Monza 352
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 336
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: a trial emulation 335
The high volume of patients admitted during the SARS-CoV-2 pandemic has an independent harmful impact on in-hospital mortality from COVID-19 332
Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient 327
HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation 324
Transaminase Decrease Upon Switch From TDF to TAF in PWH Is Modulated by HBV Status 324
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 321
Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy 320
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 309
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 309
miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis 307
Infezione disseminata da Mycobacterium avium complex con batteriemia persistente in un paziente AIDS-presenter [Disseminated Mycobacterium avium complex infection with persistent bacteremia in an AIDS-presenter patient] 304
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 298
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 295
Malassorbimento intestinale della terapia antiretrovirale in un paziente affetto da AIDS e micobatteriosi atipica disseminata 292
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 285
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 283
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 280
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 278
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 278
Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests 270
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona) 262
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 262
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 252
Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects 251
Unmasking tuberculosis in the era of antiretroviral treatment 247
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 246
High-risk HPV genotypes are associated with anal cytologic abnormalities but not with malignant histological lesions in a cohort of people with HIV (PWH) 244
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 243
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 243
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 241
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 239
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 237
Awake Prone Positioning in Adults With COVID-19 An Individual Participant Data Meta-Analysis 232
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances 230
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 227
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 224
Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study 222
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 221
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 221
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 218
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 218
Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: A cross-sectional observational study 218
Beware of biases in observational studies on anti-spike monoclonal antibodies 214
Knowledge, Use, and Misuse of Self-Prescribed Doxycycline Postexposure Prophylaxis in a Community-Based Preexposure Prophylaxis Service 214
Long-term durability of dolutegravir + darunavir/cobicistat dual regimen in highly antiretroviral-experienced people living with HIV (DoDaco study) 213
COVID-19 Mortality and Stress to the Hospital System From High Patient Load 210
Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort 209
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 203
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 202
To the editor 202
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 201
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 201
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 201
Associations between immune depression and cardiovascular events in HIV infection 200
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 197
Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19 196
COVID-19 Infection among Incarcerated Individuals and Prison Staff in Lombardy, Italy, March 2020 to February 2021 195
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 194
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 194
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 194
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study 193
Pregnant women living with HIV: the experience of IRCCS San Gerardo dei Tintori 192
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 188
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 188
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 187
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 186
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 185
Do we Still Need Eligibility Criteria to Recommend PrEP? Impact of National Prescribing Requirements on Retention in Care and Sexually Transmitted Infections Acquisition 183
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 181
Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration 178
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data 177
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: A comparison of the D: A: D CVD risk equation and general population CVD risk equations 173
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 173
Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study) 173
Unmasked tuberculosis or lymphoma in late AIDS presenters: A difficult differential diagnosis 172
Imported ciprofloxacin-resistant Neisseria meningitidis 171
Late-Onset Combined Immunodeficiency presenting with Progressive Multifocal Leukoencephalopathy and associated Immune Reconstitution Inflammatory Syndrome 170
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 170
Predictors of AIDS-defining events among advanced naïve patients after HAART 168
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 167
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 167
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 165
In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry 164
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort study 163
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 162
Pregnancy in women living with HIV: Experience of IRCCS San Gerardo dei Tintori and a narrative review 159
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: A longitudinal study 158
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 157
Mpox Virus in the Pharynx of Men Having Sex with Men: A Case Series 155
Compassionate Use of Remdesivir in Children With Severe COVID-19 155
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts >= 200 cells/mm(3) 155
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the italian atazanavir expanded access program and master cohorts 154
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 152
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: Results from the EPOKA-MASTER cohort 152
Totale 23.177
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.717
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.717
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.481 68 88 368 136 63 111 31 113 58 72 125 248
2022/20232.134 264 585 198 156 141 377 19 114 178 28 50 24
2023/20241.798 62 52 87 47 216 459 356 67 181 54 33 184
2024/20256.379 279 718 595 216 430 244 376 151 458 798 600 1.514
2025/202614.354 1.490 964 1.186 1.321 1.417 716 2.006 611 906 1.180 1.084 1.473
2026/2027457 457 0 0 0 0 0 0 0 0 0 0 0
Totale 31.068